Get the Stockscreener App
27.96
0.21%
-0.06
Pre-market:
27.87
-0.09
-0.32%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $27.96, with a volume of 27.25M.
It is down -0.21% in the last 24 hours and up +10.73% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$28.02
Open:
$28
24h Volume:
27.25M
Relative Volume:
0.66
Market Cap:
$159.36B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
21.44
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-0.39%
1M Performance:
+10.73%
6M Performance:
+1.12%
1Y Performance:
+13.66%
1-Day Range:
$27.77
$28.02
1-Week Range:
$27.77
$28.58
52-Week Range:
$23.58
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.96 | 158.39B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,174.61 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.04 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
255.48 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.35 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.81 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Advances PF-07248144 With Key Drug-Interaction Study Completion - TipRanks
Pfizer: Patient Investors Will Be Rewarded (NYSE:PFE) - Seeking Alpha
Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy. - Barron's
Mitsubishi UFJ Trust & Banking Corp Grows Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Pfizer stock holds gains after Q2 2026 earnings beat and guidance raise - Ad-hoc-news.de
Global Retirement Partners LLC Makes New $4.34 Million Investment in Pfizer Inc. $PFE - MarketBeat
Bank of New York Mellon Corp Has $1.39 Billion Position in Pfizer Inc. $PFE - MarketBeat
What Is New for Pfizer (NYSE:PFE) Across Its Oncology Pipeline? - Kalkine Media
Pfizer (PFE) Rides MRNA Cancer Optimism On A Valuation That Still Looks Modest - simplywall.st
PCF-Pfizer Visiting Professorship Program 2026 for Precision Medicine in Prostate Cancer Care - Oncodaily
Pfizer (NYSE:PFE) Shares Down 1.5%Should You Sell? - MarketBeat
Pfizer Stock's Next Chapter Might Be Hiding in Plain Sight - Trefis
Quant MF raises Pfizer stake with Rs 131 cr purchase; Pari Washington buys over 2% in Amrutanjan Health Care - TradingView
Pfizer Stock Is A Race Between New Drugs And Old Patents - Trefis
Pfizer’s Ibrance Real-World Breast Cancer Study Wraps Up: What Investors Should Watch Next - TipRanks
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead - 24/7 Wall St.
Pfizer stock hits a fresh 52-week high as Q2 2026 earnings beat and guidance lift support the rally. - Ad-hoc-news.de
KBC Group NV Sells 144,649 Shares of Pfizer Inc. $PFE - MarketBeat
Janney Montgomery Scott LLC Has $58.14 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Why Is Pfizer (NYSE:PFE) Settling Thousands of Legal Claims? - Kalkine Media
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial GainsPfizer (NYSE:PFE), Mode - Benzinga
Pfizer (PFE) Breaks to a 52-Week High at $28.24, Clearing the April Peak - 24/7 Wall St.
Pfizer (PFE) Reaches Deal Covering About 5,000 Federal Lawsuit Claims - simplywall.st
Why Pfizer (PFE) Stock Is Trading Up Today - Yahoo Finance
Pfizer (NYSE:PFE) Shares Up 3.7%Still a Buy? - MarketBeat
A Look at Pfizer Inc (PFE) After 3.6% Gain -- GF Value $26.53 vs Price $28.24 - GuruFocus
PFE Stock Quote Price and Forecast - CNN
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? - 24/7 Wall St.
Pfizer Inc Stock (PFE) Moved Up by 3.96% on Aug 19: What Signal Does It Send? - TradingKey
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions - Benzinga
Pfizer Stock Rises Wednesday: What's Going On? - Benzinga
Pfizer's Obesity Push: Can Berobenatide Take Market Share? - Yahoo Finance
Pfizer Inc (PFE): A Closer Look Behind a 68 GF Score - GuruFocus
Insider Watch: 3 CEOs Betting Millions on Their Own Stocks - TradingView
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Motley Fool
Pfizer Shares Gain 1.4% as Insider Acquisition Worth $3 Million Counters Reports of Fund Sales - TechStock²
Pfizer stock holds steady as investors weigh Q2 earnings beat and pipeline updates - Ad-hoc-news.de
Pfizer Inc. $PFE Shares Sold by Heritage Investors Management Corp - MarketBeat
TD Asset Management Inc Has $94.56 Million Stake in Pfizer Inc. $PFE - MarketBeat
Leuthold Group LLC Makes New Investment in Pfizer Inc. $PFE - MarketBeat
111 Capital Takes $3.71 Million Position in Pfizer Inc. $PFE - MarketBeat
Pfizer (NYSE:PFE) Trading Up 1.6%Here's Why - MarketBeat
Pfizer (PFE) Gets EMA Lyme Vaccine Filing Validation As ADC Patent Clout Grows - Yahoo Finance
Pfizer Pick of the Week at Smart Insider Following CEO's First Share Purchase - marketscreener.com
Pfizer: Still Cheap Valuation Meets A Looming Patent Cliff - Seeking Alpha
Pfizer Inc. $PFE Holdings Increased by Willis Investment Counsel - MarketBeat
University of Texas Texas AM Investment Management Co. Invests $3.97 Million in Pfizer Inc. $PFE - MarketBeat
Cornerstone Capital Inc. Grows Position in Pfizer Inc. $PFE - MarketBeat
Can Pfizer (NYSE:PFE) Pipeline Wins Offset Non-Cash Impairment Charges? - Kalkine Media
Albert Bourla Bought 9.6% More Shares In Pfizer - simplywall.st
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pfizer Inc Stock (PFE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | SVP & Controller |
Aug 05 '26 |
Sale |
25.40 |
3,278 |
83,261 |
28,611 |
| BLAYLOCK RONALD E | Director |
Aug 05 '26 |
Buy |
25.46 |
39,231 |
998,821 |
66,938 |
| Buckley Mortimer J | Director |
Aug 05 '26 |
Buy |
25.52 |
37,632 |
960,369 |
37,632 |
| DAMICO JENNIFER B. | SVP & Controller |
Jun 09 '26 |
Sale |
25.70 |
2,000 |
51,400 |
31,397 |
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):